Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 33  |  Issue : 2  |  Page : 599-603

Aflibercept vs ranibizumab in management of diabetic macular edema

Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Eman S Hamad
Shebin El Kom, Menoufia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mmj.mmj_302_19

Rights and Permissions

Objective The aim was to compare the efficacy of intravitreal injection of aflibercept and ranibizumab in the treatment of diabetic macular edema (DME). Background Diabetic retinopathy is a microangiopathy of the retina from which nearly all persons with diabetes eventually suffer. DME is one of its complications that threaten the patient's vision. Patients and methods This is a randomized prospective study. Fifty eyes with DME were divided into two groups (each containing 25 eyes). Eyes in group I were treated with intravitreal injection of aflibercept, and eyes in group II were treated with intravitreal injection of ranibizumab. All eyes had three successive injections. The outcomes were visual acuity and central subfield macular thickness. Results The mean baseline best-corrected visual acuity (BCVA) in group I was 0.65 ± 0.12 μm and in group II was 0.63 ± 0.19 μm (P = 0.72). After 3 months, the mean BCVA in group I improved to 0.34 ± 0.16 and in group II improved to 0.44 ± 0.21 (P = 0.10). At the end of sixth month, the BCVA was 0.42 ± 0.18 in group I and0.47 ± 0.18 in group II (P = 0.23). The mean baseline central subfield thickness (CST) of eyes in group I was 523.8 ± 105.3 μm and in group II was 477.4 ± 143.6 μm (P = 0.11). After 3 months, the mean CST in eyes of group I decreased to 348.04 ± 98.4 μm, whereas in eyes of group II, the mean CST decreased to 377.5 ± 115.7 μm (P = 0.031). After 6 months, the mean CST in the eyes of the group I became 373.6 ± 139.8 μm, whereas in eyes of group II became 371.7 ± 102.3 μm (P = 0.96). Conclusion Aflibercept and ranibizumab have the same efficacy in the treatment of DME.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal